Eliglustat (CAS 491833-29-5) – Glucosidase Inhibitor API

Eliglustat (CAS 491833-29-5) is a high-purity, selective glucosidase inhibitor API with a targeted mechanism that blocks glucosylceramide synthase activity. Its unique molecular structure inhibits the synthesis of glucosylceramide, a key glycosphingolipid, preventing its accumulation in cells and tissues. Produced under strict GMP-compliant processes, it ensures ultra-high purity, consistent bioactivity, and compliance with global rare disease pharmaceutical standards.

This premium API is a core raw material for pharmaceutical manufacturers developing treatments for Gaucher disease type 1, a rare lysosomal storage disorder. It is designed for oral administration, offering a convenient alternative to enzyme replacement therapy for eligible patients. With proven clinical efficacy in reducing disease-related symptoms and improving patient quality of life, it addresses the unmet medical needs of rare disease populations. For R&D teams and production enterprises, it provides a trusted solution to advance rare disease therapy development.